SunTrust Downgrades Zafgen (ZFGN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St climbs as Mideast tensions ease, Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- The next banking crisis may come from cyberattacks, not credit losses: JPMorgan
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Leerink Partners Downgrades Zafgen (ZFGN) to Market Perform
December 3, 2015 11:02 AM ESTLeerink Partners downgraded Zafgen (NASDAQ: ZFGN) from Outperform to Market Perform with a price target of $7.00 (from $11.00) after further lowering probability of success for beloranib to 30% (from 40% previously) in our SOTP DCF analysis since the threshold for justifying risk-benefit has considerably been increased w/... More
